MUSC Psychiatry Chair
Update
January 2016

Thomas W. Uhde, MD
Department of Psychiatry and
Behavioral Sciences & Institute of
Psychiatry
Therese Killeen APRN PhD, Research Associate Professor in the Department of Psychiatry and Behavioral Sciences, has worked in the area of Addictions and Comorbidity over the last 25 years. Dr. Killeen was part of the team that started addiction treatment services in the Dept. of Psychiatry. Over the years, she has served as principal and co-investigator on numerous psychosocial and pharmacotherapy studies and is well published in this area. As a co-investigator of the National Institute of Drug Abuse (NIDA) Clinical Trials Network for the past 15 years, her work has centered on disseminating evidence-based interventions in community treatment programs. Dr. Killeen has trained and supervised numerous community clinicians and supervisors in such approaches as motivational interviewing, contingency management, and other cognitive behavioral approaches for treating addiction and comorbid disorders. Dr. Killeen works with community programs to adapt interventions to increase the likelihood of implementation and adoption.

She has been a member of the Motivational Interviewing Network of Trainers for the past 13 years, adapting her training to meet the needs of diverse populations. Dr. Killeen is co-author of the recently published COPE therapist and patient manuals for treating co-occurring PTSD and SUD using prolonged exposure. Together with Dr. Sudie Back, she has conducted numerous National and International training workshops in this approach. Dr. Killeen was recently awarded an NIDA R01 to explore the use of mindfulness based relapse prevention for the treatment of women with PTSD and SUD enrolled in community based treatment.

In her off time Dr. Killeen is an avid runner and enjoys traveling.
Dr. Kathy Magruder is an epidemiologist and tenured Professor in the Division of Military Sciences and holds a joint appointment in the Department of Public Health Sciences. She is also the Director of the Office of Research Integrity. Dr. Magruder received a BA in Psychology from Duke University and an MPH and PhD in Epidemiology from the School of Public Health, University of North Carolina at Chapel Hill. Before coming to MUSC, she worked at NIMH as the Director of the Office of Rural Mental Health and the Chief of the Services Research Branch. In 2011-12 she was selected for a Fulbright Award (Senior Researcher) in Ankara, Turkey. In 2014 she was the recipient of the H.A. Tyroler Distinguished Alumni Award, University of North Carolina at Chapel Hill, Epidemiology Chapter of the Gillings School of Global Public Health Alumni Association. Dr. Magruder is Associate Editor for the Journal of Traumatic Stress. She is an active member of the International Society for Traumatic Stress Studies, the European Society for Traumatic Stress Studies, and the American Public Health Association.

Dr. Magruder’s primary research interests are related to PTSD among aging veterans and public health approaches to studying trauma and stress. She has just completed two large VA studies related to long-term health and mental health outcomes in national samples of community dwelling Vietnam Era male and female veterans with a recent publication in *JAMA-Psychiatry* and a forthcoming one in the *Journal of Traumatic Stress*. In October she delivered a keynote address entitled “40 Years Later: the Legacy of Vietnam for US Male and Female Veterans” at the Australasian Military Medicine Association Conference, Hobart, Tasmania, Australia.

Dr. Magruder is an active member of the Isle of Palms Turtle Team, and in the summers (if she’s not travelling to some exotic place) you can find her jogging and looking for turtle nests on the beach in the early morning.
Dr. Flanagan is an Assistant Professor in the Addiction Sciences Division of the Department of Psychiatry and Behavioral Sciences. She received a B.A. in psychology at the University of Vermont in 2003 and a Ph.D. in clinical psychology at the University of Tennessee 2011. She completed her clinical psychology internship training at the Seattle VA and a NIDA-funded T32 postdoctoral fellowship at the Yale University School of Medicine before joining the faculty as a scholar in the NICHD/ORWH-funded K12/BIRCWH program at MUSC in 2013.

Dr. Flanagan’s program of research focuses on understanding factors that precipitate violent behavior, with a specific focus on the association between substance use disorders, posttraumatic stress, and intimate partner violence among civilian and military populations. Recently, her research has transitioned to integrate neurobiological assessment and dyadic adaptations of human laboratory procedures as well as pharmacological interventions to facilitate the study of treatment development in this area. Her BIRCWH project examined the effects of oxytocin on laboratory-based conflict resolution behaviors among couples with substance use disorders and is currently working to adapt a validated neuroimaging procedure for use among couples in future treatment development efforts. She is also PI of a SCTR-funded pilot project examining the safety, feasibility, and acceptability of augmenting Prolonged Exposure therapy for PTSD with oxytocin and a co-investigator on several other DoD, VA, and NIH-funded developing novel behavioral and pharmacological interventions to reduce co-occurring PTSD and substance use disorders.

Dr. Flanagan specializes in treating patients utilizing Prolonged Exposure and other cognitive behavioral models including dyadic interventions for PTSD and substance use disorder. She also contributes to the mentorship and clinical supervision of trainees in the psychology internship and psychiatry residency programs at MUSC.
Phillippe B. Cunningham, a native of Washington, DC, completed the requirements for a Ph.D. in Clinical Psychology from Virginia Polytechnic Institute and State University and completed a Pre-Doctoral Internship with the Department of Psychiatry and Behavioral Sciences of the Medical University of South Carolina (MUSC). Dr. Cunningham is a Professor in the Department of Psychiatry and Behavioral Sciences, Family Services Research Center (FSRC) Division. He has had a longstanding commitment to addressing the psychosocial needs of children and adolescents, especially those who are disadvantaged and under served. His clinical and research interests include (1) Developing culturally competent mental health services; (2) Evaluating innovative clinical services for disadvantaged youth and families; (3) Developing and evaluating community-based prevention and intervention services; and (4) Training and supervising mental health professionals in providing innovative and evidence-based services. In 2000, Dr. Cunningham received the Theodore H. Blau Early Career Award from the American Psychological Association’s Society of Clinical Psychology. In 2006, Dr. Cunningham participated in the First Lady’s Conference on “Helping America’s Youth.” Dr. Cunningham has also served as a member of the White House Office of National Drug Control Policy National Youth Anti-Drug Media Campaign Behavior Change Expert Panel.

As an African American clinical psychologist with national recognition in the development of behavioral interventions for ethnic minority families as well as in culturally competent intervention delivery, he has served as a Principal Investigator on an NIMH-funded study “Culturally Competent Mental Health Services for Children” (RO3 MH59124-01) designed to evaluate therapist cultural competence in the delivery of Multisystemic Therapy (MST). This research has been a part of a programmatic effort to operationalize cultural competence by systematically examining actual within session therapist behavior. This work led to recent funding from the Fahs-Beck Fund for Research and Experimentation (“Midtreatment Implementation Problems in Evidence-Based Treatments for Youth”). As a FSRC faculty member, Dr. Cunningham collaborated with the former Center Director, Dr. Scott Henggeler, in conducting many of the pioneering outcome studies of MST, a comprehensive evidence-based treatment. For over two decades, he has been involved in the further development and dissemination of MST. As part of this collaboration, Dr. Cunningham spearheaded the adaptation and integration of Contingency Management (CM) interventions into MST. In addition, during the last 10 years he has been directly involved in the dissemination of CM within the MST provider network and have served as a Co-Investigator on several National Institute on Drug Abuse-funded CM dissemination studies (DA017487, “Testing Therapist Training Interventions to Implement EBT to Adolescents,” PI: Henggeler; DA017487 “Enhancing Juvenile Drug Court Outcomes with EBP’s,” PI: Henggeler; DA034064, “Testing a promising Treatment for Youth Substance Abuse in a Community Setting” PI: Henggeler). Dr. Cunningham was also the principal investigator of a NIMH-funded study examining treatment non-responders (MH068813-02 “Differential Response to Evidence-Based Treatment”) that included an examination of barriers to parent’s participation in evidence-based treatment.

In addition to completing an original adaptation of MST to address youth substance abuse, in collaboration with Wayne State Investigators, Dr. Cunningham has played a major role in adapting MST for children and adolescents with chronic conditions (including obesity, asthma, HIV infected children, adolescents with chronically poorly controlled diabetes, and adolescents who are poorly adherent to their antiretroviral medications). Most recently, he served as an investigator on a recently completed study examining MST with urban African American youth with moderate to severe asthma and a history of emergency department recidivism or hospitalizations.
CHAIRMAN’S RESEARCH DEVELOPMENT FUND

The Chairman of the Department of Psychiatry and Behavioral Sciences is pleased to announce a new submission cycle for the Chair’s Research Development Fund (CRDF). Applications will be accepted until midnight, May 1st. The CRDF supports several goals related to maintaining high quality research training programs. The primary goals are to increase the number of extramurally-funded junior investigators, encourage integration of trainees into research projects, enhance mentor-mentee collaborations within and across department divisions, and increase minority representation among funded junior investigators.

For more information, please contact Vickey Cornelison-Grant at cornelv@musc.edu, or call her at 792-5879.

SPRING CYCLE FOR PROMOTION & TENURE

For anyone who is requesting promotion or tenure effective January 1, 2017, all promotion and tenure requests must be received in the Chairman’s office no later than February 9, 2016, in the form of complete packets accompanied by a letter of recommendation from your Division Director. Packets with checklists, requests for materials, and forms specific for regular and modified faculty have been developed to make the submission process more straightforward. Packets are available on the College of Medicine’s website. Follow this link: http://academicdepartments.musc.edu/com/faculty/apt/musc/index.html. The letter of recommendation from your Division Director must follow appendix 2 in the COM APT guidelines. Division Director letters should include the following paragraphs: introductory, education, research if applicable, scholarly publications, clinical practice if applicable, administration, and other activities and accomplishments. If you have any questions, please contact Kristen Mulholland mulhollk@musc.edu.
KUDOS/WINS

- Dr. Gregg Dwyer was an invited speaker at the Low Country Crisis Negotiator Team Training in Charleston. The titles of his presentations are as follows: Negotiators and Stress: Prevention and Management and Law Enforcement Negotiation and Mental Illness: An Overview

- Dr. Dean Kilpatrick chaired a workshop on trauma sponsored by the National Academy of Sciences. Drs. Kilpatrick and Saunders presented papers at the workshop.

- Dr. Gregg Dwyer was elected Distinguished Fellow of the American Psychiatric Association (APA). The convocation will occur during the 2016 APA meeting.

- Drs. Matt Carpenter and Michael Cummings were featured in the Post and Courier’s “Your Health” section discussing the Quit and Win smoking contest.


- Dr. Gregg Dwyer was an invited presenter for the MUSC College of Medicine Faculty Development Roundtable and presented “Academy of Medical Educators: An Introduction and Overview.”
BREAKFAST WITH THE CHAIR

I have implemented monthly breakfast meetings. These meetings are intended to have an open-ended discussion with the Chair regarding education/training, clinical service, and/or research opportunities and future strategic plans. Available dates in 2016 include: February 2, March 15, April 12, May 24, June 21, July 19, September 13, October 11, and November 15. Breakfast meetings will be held from 8:30am-9:30am in the Chairman’s conference room and are open to a maximum of 12 faculty members. Interested faculty members should contact Kristen Mulholland (mulhollk@musc.edu) to sign up for a breakfast meeting.

FACULTY MEETINGS

All faculty members are expected to attend Faculty Meetings. Faculty Meetings are held quarterly from 12-1pm in the IOP Auditorium. Attendees are eligible to win $1,000 incentive to be used for dues, subscriptions, memberships in professional societies, educational purposes, etc.

2016 FACULTY MEETING DATES:

- January 19, 2016
- April 19, 2016
- July 19, 2016
- October 18, 2016

NEW HIRES

New Hires—Institute of Psychiatry:

- Tarasha Evans
- Tamara Newton
- Ray Orvin, III
- Danielle Sinkler
- Meagan Smalls
- Beverly Tabor
Please join us for a Comings and Goings celebration

Please join us as we recognize new faculty and employees and say farewell to those leaving us.
January 28, 2016
Institute of Psychiatry Lobby
11:30-12:30pm
desserts and refreshments will be served

FACULTY RECEPTION

You are cordially invited to the
Department of Psychiatry & Behavioral Sciences

Faculty Reception
March 1, 2016

Wickliffe House
5pm-7pm

Please RSVP to Kristen.Mulholland (mulhollk@musc.edu) by February 22, 2016.
### GRANT AWARD ACTIVITY
#### 12.1.15-12.31.15

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudie Back</td>
<td>RCT of tDCS-Augmented CBT for Veterans with Pain and Co-Morbid Opiate Misuse</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>Jeffrey Borckardt</td>
<td>RCT of tDCS-Augmented CBT for Veterans with Pain and Co-Morbid Opiate Misuse</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>K. Michael Cummings</td>
<td>Monitoring and Assessing the Impact of Tax and Price Policies on US Tobacco Use</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>Colleen Hanlon</td>
<td>Longitudinal Study of Functional Connectivity Among Cocaine Users in Treatment</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>Alyssa Rheingold</td>
<td>Violence against Hispanic Women Network</td>
<td>Competing Continuation</td>
</tr>
<tr>
<td>Alyssa Rheingold</td>
<td>Enhanced Victim Services to Address Needs of Rural Homicide Survivors</td>
<td>New</td>
</tr>
<tr>
<td>Zhewu Wang</td>
<td>Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study (IPA: Voltin)</td>
<td>New</td>
</tr>
<tr>
<td>Zhewu Wang</td>
<td>Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled, Feasibility Study</td>
<td>New</td>
</tr>
</tbody>
</table>

### DR. GEORGE PRESENTATION

Dr. Mark George will be giving a presentation on Wednesday, February 10 at 6pm in the IOP Auditorium as part of the College of Charleston Darwin Week. His talk is titled *Is the Emergence of Consciousness an Inevitable Consequence of Evolution?* The mind-brain problem and the question of the neural basis of consciousness are some of modern science’s hardest questions. To say that an organism has conscious experience implies self-awareness. Dr. George will argue that even a crude conceptualization of an ‘I’ or ‘me’ would confer large evolutionary advantage for memory and planning. Darwinian principles, applied to the brain, suggest that life on earth has likely and perhaps inevitably evolved to create creatures like us, humans, who are conscious.


Wangelin BC, Tuerk PW. TAKING THE PULSE OF PROLONGED EXPOSURE THERAPY: PHYSIOLOGICAL REACTIVITY TO TRAUMA IMAGERY AS AN OBJECTIVE MEASURE OF TREATMENT RESPONSE. Depress Anxiety. 2015 Nov 2.


IOP PATIENT FAMILY ADVISORY COUNCIL

To Institute of Psychiatry Health Care Providers:

This year, the Institute of Psychiatry Patient Family Advisory Council will celebrate 5 years of supporting the patients and families we serve by strengthening partnerships among patients, families, health care providers and our community. Over these years, the council has experienced some natural attrition and needs to recruit additional council members to boost its membership. Therefore, the council is requesting your assistance with a council member recruitment campaign (recruitment flyer for distributing / displaying attached).

We are asking our Institute of Psychiatry health care providers to consider and identify patients or family members who would make a meaningful contribution to this council. The candidates must:

• have a patient or family member experience through inpatient and/or outpatient services of the Institute of Psychiatry.
• be able to participate in MUSC Volunteer Services screenings and orientation activities.
• be able to attend monthly meetings, share input and participate in council projects.
• be positive and supportive of the MUSC’s mission and standards of professional behavior.
• be able to see beyond their own personal experiences.
• listen well and respect the perspectives of others.
• be able to speak comfortably in a group with candor and work in partnership with others.

Patients and family members can bring valuable perspectives about their treatment experiences at the Institute of Psychiatry and provide unique insights into the strengths and challenges of the mental health care system. The IOP Patient Family Advisory Council has been an active and productive team of volunteers. Council members have shared their recovery stories as part of IOP department orientation, participated on committees and process improvement teams, facilitated programs that promote mental illness education and awareness and utilized grants to fund projects that support recovery.

Please send the names of patients and/or family members and contact information to: Bryan Counts, IOP Patient Safety & Service Coordinator: countsbc@musc.edu / 792-6259.
DART SUMMER RESEARCH FELLOWSHIP APPLICATIONS

We are now accepting applications for the 2016 NIDA-funded Summer Research Fellowship in the Drug Abuse Research Training (DART) program at MUSC, Department of Psychiatry and Behavioral Sciences. The DART summer program is a structured 10-week, mentored training program for medical students, graduate students, and undergraduate students. The goal of the DART summer program is to introduce promising students to research, both basic science and clinical in nature, and afford them the opportunity to work closely with a research mentor and his/her investigative team.

A stipend of $3,000 is provided. The application deadline is February 1.

For more information please email Ms. Vikki Bernotski at bernotsk@musc.edu or visit our website: http://academicdepartments.musc.edu/psychiatry/addiction-sciences/research/DART/dart-summer
Cutting Edge: What's New In Sex Offender Treatment and Assessment

Come join us for a day long training and conference to discover what's new and current in the field of Sex Offender Treatment.

Friday, February 5, 2016
Medical University of South Carolina
Bioengineering Building, Room 110
9 a.m. - 4:30 p.m.

This training offers presentations by local experts in the areas of assessment and treatment of adults, juveniles, and female sex offenders. The day will conclude with an open panel discussion with the board members of our state chapter of ATSA. So bring your questions and receive some expert advice.

This is a great opportunity to network with other individuals who work in the field and to establish relationships to assist in becoming a member of the national organization. We look forward to seeing you all at this event.

Registration Fees:

<table>
<thead>
<tr>
<th></th>
<th>Early Registration (thru 12/31/15)</th>
<th>Regular Registration (1/1/16 - 1/24/16)</th>
<th>Late Registration Fee (1/25/16 - 2/3/16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD</td>
<td>$150.00</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Other Providers</td>
<td>$100.00</td>
<td>$125.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Students/Trainees</td>
<td>$50.00</td>
<td>$75.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>

CEU's are available to attendees

To register online for this training and view all our upcoming events, visit us at: www.musc.edu/psychevents
ONGOING STUDIES

Title: Eagle Eye: Validation of computer-based saccade measures as a sensitive, reliable, and freely available biomarker for tracking subtle neurocognitive changes in Parkinson's disease.
Sponsor: Michael J. Fox Foundation
Contact: Jenna Renfroe, PhD; renfroe@musc.edu ; 843-792-6096
Description: This study aims to validate a computer-based task to enable clinicians and researchers to measure saccades without the cost and complexity of traditional eye-tracking equipment.

Title: Development and standardization of an iPhone-based application for quantitative measurement of the pupillary light reflex in healthy adults and patients with Parkinson’s disease. (iDilate)
Sponsor: Chairs Departmental Research Foundation
Contact: Jenna Renfroe, PhD; renfroe@musc.edu ; 843-792-6096
Description: This aim of this project is to develop and standardize an application that would allow clinicians, researchers, and community-based safety personnel (e.g., police and EMS) to obtain quantitative measurements of the pupillary light reflex, a highly sensitive measure of neurological functioning.

Title: Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog).
Sponsor: Michael J. Fox Foundation
Contact: Vanessa Hinson, MD, PhD.; hinsonvk@musc.edu ; 843-792-6096
Description: This is a RCT assessing the safety and efficacy of ATM for cognitive impairment in Parkinson’s disease.

Title: Ranger Resilience and Improved Performance on phospholipid bound Omega-3’s (RRIP-3).
Sponsor: Aker Biomarine
Contact: Travis H. Turner, PhD; turnertr@musc.edu ; 843-577-5011 x5192
Description: This is a RCT examining whether supplementation with phospholipid bound omega-3 improves resiliency to psychophysiological distress in a sample of 400 candidates going through Infantry Basic Officer Leadership Course (IBOLC) and subsequent Ranger training at Ft. Benning. In addition to grades from IBOLC and success/failure in Ranger training, a number of neuropsychiatric measures are included as outcome and mediator/moderator variables.

Title: Better Resiliency Among Veterans with Omega-3’s (BRAVO)
Sponsor: Congressionally Directed Medical Research Program.
Contact: Samantha Wise ; wissa@musc.edu ; 843-792-2425
Description: This RCT seeks to determine if dietary supplementation with omega-3 HUFAs reduces the risk for serious suicidal behaviors in an at-risk clinical population. Changes in cognitive processes specific to suicide risk are evaluated, including implicit associations, response inhibition and sustained attention.
**ONGOING STUDIES**

**Title:** Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients

*PAM-ICD Trial (NCT02088619)*

**Contact:** Dr. Lily Christon (Project Coordinator); Dr. Eva Serber (PI)

**Contact email:** pam-icd@musc.edu

**Contact phone number:** 843-792-0625

**Description:** This study is a randomized clinical trial of a positive-emotion focused cognitive-behavioral therapy intervention (Quality of Life Therapy) vs. a heart healthy education intervention among patients with implantable cardioverter defibrillators (ICD), with the primary aim of feasibility and acceptability of QOLT in ICD patients. Secondary aims include obtaining effect size estimates of QOLT on frequencies of arrhythmia episodes and ICD-delivered therapies, parasympathetic activity and regulation, and QOL and psychosocial constructs. Recruitment: patients of MUSC Cardiology

---

**Title:** TMS for nicotine addiction

**Contact:** Scott Henderson or Xingbao Li

**Contact email:** henderjs@musc.edu or lixi@musc.edu

**Contact phone:** 843-792-5560 or 843-792-5729

**Description:** This is a double blind randomized controlled smoking cessation research study sponsored by the National Institute of Drug Abuse. This study is designed to ascertain whether repetitive transcranial magnetic stimulation (rTMS) can affect things that may prompt you to want to smoke and the consumption of cigarettes over a 3-month period. After assessment and inclusion into the study, participants will be randomized to receive a 10-time active rTMS or placebo-like rTMS. Participants must be (1) current cigarette smokers; (2) between 18-60 years old; (3) able to commit approximately 13 hours of time to the study; and (4) have no metal in their body. Compensation will be provided.

---

**Title:** Integrative Risk Reduction and Treatment for PTSD and Teen Substance Use Problems

**Contact:** Liz McGuan, mcguan@musc.edu, 843-792-8361

**Description:** This program involves a randomized controlled trial (RCT) with subjects ages 13-18 years who have experienced interpersonal violence (physical or sexual abuse/assault, exposure to domestic violence, witness community violence). Subjects are randomized to either receive Risk Reduction through Family Therapy (RRFT) or Treatment As Usual (TAU). Youth will be recruited from local child advocacy centers and the interventions are psychosocial in nature. Follow-up assessments will be conducted at multiple time points through 18-month post entry.

---

**Title:** Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus

**Contact:** Suzanne Kuker, kuker@musc.edu, 792-5427

**Description:** This study seeks to determine whether semaglutide will help non-diabetic people who are obese to lose weight over one year. Participants will be randomly assigned to receive 1 of 5 doses of semaglutide, liraglutide or an inactive placebo and will be enrolled in the study for 59 weeks. The primary measure will be weight change and other measures will include health factors related to obesity such as blood sugar control, blood pressure, and cholesterol. The safety of the drug for weight loss will also be studied.
Title: Group Motivational Interviewing (GMI) for Homeless Veterans in VA Services
Contact: Kayla Lamb, Kayla.Lamb@va.gov, 843-577-5011 ext: 5310
Description: We are seeking Veterans who are homeless or in the VA Homeless Program to voluntarily enroll in a VA research study comparing two types of treatment for Veterans who have an alcohol misuse problem. Eligible participants will attend one of two groups: a motivational enhancement group therapy, called ‘The Self-Change Program’, designed to enhance motivation to make a healthier change around using substances by exploring personal goals, values, and strengths for making a change, or a Like Skills Educational Group therapy for improving quality of life and enhancing home stability. The study will recruit participants from within three locations: the Charleston VA Medical Center, the Myrtle Beach Community Based Outpatient Clinic (CBOC), and the Savannah, GA CBOC. Compensation will be provided to qualified participants.

Title: A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Contact: Amanda Wagner, wagne@musc.edu, 843-792-0484
Description: This is a randomized, placebo-controlled, double-blind clinical trial (Phase III) evaluating the safety and efficacy of an investigational medication called Dasotraline in adults with Attention Deficit Hyperactivity Disorder. The study requires weekly visits for 12 weeks, and daily medication compliance.

Title: Smart Capsule for Automatic Adherence Monitoring
Contact: Elizabeth Jones, jonesel@musc.edu, 843-792-5819
Description: The purpose of this study is to determine the acceptability, tolerability, and efficacy of capsules with built-in, ingestible sensors that allow researchers to tell whether or not a patient took them as prescribed. This study is recruiting healthy volunteers.

Title: Effects of transcranial Direct Current Stimulation and Brief Cognitive Intervention on Pain Tolerance.
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The Departments of Psychiatry and Anesthesiology at MUSC are accepting volunteers for a clinical research study to investigate pain tolerance. The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS) can temporarily alter pain tolerance level. tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain perception. Interested participants will be screened on the telephone and then have one appointment lasting approximately 1 hour. Participants must be between the ages of 18 and 75. Participation is confidential, and compensation is available.
ONGOING STUDIES

Title: The Effects of Cognitive Behavioral Therapy and Transcranial Direct Current Stimulation (tDCS) on Fibromyalgia Patients
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS), can help reduce fibromyalgia and reduce the need for pain medication when applied in combination with cognitive behavioral therapy (“talk therapy”). tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain reduction. Some preliminary studies suggest that tDCS may be effective in reducing fibromyalgia and altering pain perception in both healthy adults and in patients with various types of pain conditions. Participants must be between the ages of 21 and 85. Participation is confidential, and compensation is available.

Title: Preliminary Study Investigating Whether Low Field Magnetic Stimulation (LFMS) Has Antinociceptive Effects In A Laboratory Pain Model
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The purpose of this study is to determine whether a new form of non-invasive brain stimulation, called low field magnetic stimulation (LFMS), can relieve pain. LFMS is like another form of brain stimulation called transcranial magnetic stimulation (TMS). This study consists of a 30 minute screening visit and two 90-minute experimental trials separated by approximately one week. Participation is confidential, and compensation is available.

Title: The Effects of Cognitive Behavioral Therapy and Transcranial Direct Current Stimulation (tDCS) on Chronic Lower Back Pain
Contact: verteranpainsc@gmail.com, 843-779-2493
Description: The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS), can help reduce chronic lower back pain and reduce the need for pain medication when applied in combination with cognitive behavioral therapy (“talk therapy”). tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain reduction.
• COMPENSATION PROVIDED
• ALL INFORMATION IS CONFIDENTIAL
PARTICIPANTS MUST:
• Be between the ages of 18 - 70
• Suffer from chronic pain
• Be a United States Veteran
• Take a prescription pain medication
ONGOING STUDIES

Title: rTMS for Adolescent Depression -- upcoming in the next couple weeks
Contact: Annabel Franz, franza@musc.edu, 843-876-5141
Description: We are investigating the safety and efficacy of repetitive TMS as a treatment for adolescent depression for those aged 12-21 years old. We are seeking adolescents of this age range who have not received sufficient benefit from at least one antidepressant medication trial. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Bipolar Depression - current
Contact: Annabel Franz, franza@musc.edu, 843-876-5141
Description: We are investigating repetitive TMS as a treatment for bipolar depression in conjunction with mood stabilizers in adults aged 22-68 years old. We are seeking treatment refractory patients with bipolar disorder. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Reducing Marijuana Craving and Risky Behaviors in Non-Treatment Seeking Heavy Marijuana Smokers - current
Contact: Annabel Franz, franza@musc.edu, 843-876-5141
Description: A pilot trial investigating how TMS to the left dorso-lateral pre-frontal cortex can reduce marijuana craving and impulsive decisions in adults 18-60.

Title: Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity & Use
Contact: Amanda Smith, smitham@musc.edu, 792-6984
Description: The purpose of this double-blind, placebo-controlled study is to examine whether beta-adrenergic antagonist propranolol can attenuate cocaine-associated memories and thereby reduce cocaine craving, cue reactivity, and use in cocaine dependent participants. Participants will receive either placebo, 40mg, or 80mg of propranolol after each of two laboratory sessions of cocaine cue exposure. Participants will be evaluated on cocaine craving, physiological reactivity to cocaine cues, and cocaine use in follow-up sessions for 6 weeks.

Title: Traumatic Exposure and Competency to Stand Trial: Describing Juvenile Offender Characteristics.
Contact: Sheresa Christopher, chrisshe@musc.edu, 792-1461
Description: Exposure to traumatic events is associated with trauma sequelae which has been studied and observed in samples of justice-involved youth. Within this population, a small subset of youth is referred for evaluation of their competency to stand trial due to concerns they may be lacking a factual and rational understanding of the proceedings against them and the ability to assist their attorney in their defense. Despite the high prevalence of trauma exposure and the similarity of deficits observed, little is known about trauma exposure in youth thought to exhibit deficits in those abilities typically associated with competency to stand trial. The current study aims to describe the differences in characteristics between juveniles who are opined competent to stand trial and those who are not. A particular emphasis is placed on the presence and type of past trauma exposure in relation to the nature of the criminal offenses given the high prevalence of trauma in this population.
ONGOING STUDIES

Title: Comparison of Pre-Trial Competency to Stand Trial Defendants’ Characteristics on Outcome of Feigning Measures: A Preliminary Study of Local Norms  
Contact: Jennifer Steadham, steadhaj@musc.edu, 876-2140  
Description: Deliberate attempts to falsify, fabricate, or grossly exaggerate some aspect of functioning is known as feigning. When feigning is motivated by possibility of external gains (e.g., avoidance of prosecution or lesser punishment), it is known as malingering (Rogers & Shuman, 2005). Malingering has obvious relevance in forensic mental health evaluations, as pre-trial criminal defendants have clear motivations to feign impairment. Feigning strategies can be subdivided into two varieties in criminal forensic contexts: cognitive (i.e., memory or thinking processes) and psychiatric (i.e., symptoms of major mental disorders) impairment. Categorical classifications can be made on the basis of a defendant’s performance on feigning assessment measures, into groups thought to be exaggerating or fabricating impairment (“probable malingers”) or those thought to be responding honestly (“non-malingerers”). In the last decade, direct examinations comparing the characteristics of competency defendants suspected of malingering versus non-malingers, as classified by feigning measures, have been sparse and most often included as an incidental question in a larger study. For the current study, a sample of competence to stand trial evaluations conducted by MUSC’s Forensic Psychiatry Program will be reviewed. Competency to stand trial reports dated 2011 through August 2015 will be included for review. Evaluation reports will be coded for examinee (e.g., demographic, psychiatric diagnoses, and mental status descriptions) and evaluator characteristics (i.e., specialty field).

Title: CSP556 “rTMS for depressed veterans”  
Contact: Matt Schmidt, matthew.schmidt@va.gov, 843-577-5011 ext 5209  
Description: This is study for veterans only who have depression. The treatment given is Transcranial Magnetic stimulation. It is a double blind study with a sham (placebo) possibility. There is a screening phase of about 1 week, a treatment phase of 4-6 weeks, and a follow up phase where subjects come in once per month for 5 months. All procedures and assessments done at Ralph Johnson VA. Subject compensation is available up to $400.00.

Title: A Randomized Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use  
Contact: Caitlyn Hood, hooca@musc.edu, 843-876-2291  
Description: Electronic cigarettes (e-cigarettes) are the newest and perhaps the most popular non-cigarette products available to smokers. In this study, we will examine how the use of electronic cigarettes affects smoking behavior. Eligible participants will have a 2/3rds chance of receiving a sample of e-cigarettes. Participants must be current, daily cigarette smokers who are 18 years of age or older and interested in trying the e-cigarette.

Title: Oxytocin in Cocaine Dependence  
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476  
Description: This study explores the effect of oxytocin on stress response and brain reactivity in individuals with cocaine dependence. Participation consists of a screening visit, three outpatient study sessions, and two brief follow-up visits.
ONGOING STUDIES

Title: Effect of Pregnenolone on Cue-Reactivity in Marijuana-Dependent Individual.
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the impact of an oral medication, pregnenolone, on drug craving following exposure to marijuana cues. Participation consists of a screening visit and one study session.

Title: Neural Substrates of Emotion: Impact of Cocaine Dependence
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the effect of oxytocin on brain activity associated with stress in cocaine dependent individuals. Participation consists of a screening visit and one study session.

Title: A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation (formal title protocol); Project Quit (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a research study to determine if a medication (varenicline) helps young cigarette smokers quit. Smokers aged 14-21 who participate in the study receive medication or placebo and help with quitting during 12 weekly sessions. Smokers under 18 must have parental consent. There is no cost to participate and compensation is available to those that qualify.

Title: The gender-sex hormone interface with craving & stress-related changes in smoking (formal title protocol); SCOR 3 Nicotine (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a non-treatment study for cigarette smokers ages 18-45, examining gender and reproductive hormone influences on smoking behavior. There is NO requirement that participants be interested in quitting smoking. The study involves 4 clinic visits and compensation is provided for those who qualify.

Title: Gabapentin for Relapse Prevention: Alcohol Withdrawal-Brain GABA/Glutamate Effects
Contact: Konstantin Voronin, voronin@musc.edu, 792-4887
Description: This treatment study is an 16-weeks outpatient clinical trial where subjects will get medication, which might help them to reduce or stop their drinking, or a placebo. This study will recruit and randomize subjects who have expressed an interest in receiving treatment for alcohol dependence. Upon enrollment into this study there will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
ONGOING STUDIES

Title: Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication  
Contact: Mark Ghent, ghent@musc.edu, 792-1222  
Description: This non treatment study investigates the effects of a medication in response to alcohol. Individuals (ages 21-40) who complete the study will be paid for their participation. This study does not involve alcohol treatment.

Title: Acceptability and feasibility of the remote monitoring of smoking and relapse in adolescents  
Contact: Taylor York, york@musc.edu, 843-792-0493  
Description: This is a research study that will test a new remote monitoring technology to assess smoking in the natural environment among adolescents and young adults ages 15-25. After assessment and inclusion in the study, participants will be asked to carry two devices (smartphone and a device to assess how much they are smoking) with them for 11 days and answer questions about their smoking, mood, surroundings, etc. Participants will also be asked to make a brief quit attempt lasting for approximately 48 hours. There is no cost to participate and compensation is available to those who qualify. Remote monitoring technology has the potential for fewer clinic visits and a better understanding of smoking among adolescents and young adults.

Title: A novel approach to reduce the use, misuse and abuse of prescription opioids in pregnancy  
Contact: Connie Guille, guille@musc.edu, 843-792-6489  
Description: The aim of this study is to gather feedback from pregnant women using prescription opioids who participate in a Cognitive Behavioral Therapy for Chronic Pain program for the reduction of use, misuse and abuse of prescription opioid medication(s).

Title: Adverse early childhood experience and risk for poor obstetric outcomes in African American women  
Contact: Connie Guille, guille@musc.edu, 843-792-6489  
Description: The aim of this study is to investigate the impact of early childhood adversity on a laboratory stressor and risk for poor obstetric outcomes.

Title: Testing a Promising Treatment for Youth Substance Abuse in a Community Setting  
Contact: Dr. Scott W. Henggeler, henggesw@musc.edu, (843) 876-1800  
Description: The overriding purpose of the proposed randomized trial is to examine the effectiveness of a promising outpatient treatment of adolescent substance abuse delivered in a community-based treatment setting.

Title: Family-Based Treatment for Parental Substance Abuse and Child Maltreatment  
Contact: Dr. Cynthia C. Swenson, swensocc@musc.edu, (843) 876-1800  
Description: The purpose of this randomized controlled trial is to examine the effectiveness of the Building Stronger Families Model versus standard services in Connecticut for physically abuse and/or neglected children whose parents are experiencing severe substance abuse. The study is being implemented through a community based mental health provider. Key outcomes under examination include child behavior, parent behavior, family relations, parent to child violence, reabuse, placement, and parental substance abuse.
Title: Psychological First Aid for Victims of Crime  
Contact: Dr. Michael McCart, mccartm@musc.edu, (843) 876-1800  
Description: This study aims to implement and refine research protocols required for a full-scale randomized clinical trial of Psychological First Aid (PFA) for adult victims of crime. PFA is a promising acute intervention designed to reduce the severity and duration of trauma-related distress. Law Enforcement Victim Advocates are being trained to implement PFA with adult crime victims. A pilot trial is comparing PFA to usual services on key mental health outcomes from baseline through 4 months post-baseline.

Title: Synthesizing HIV Behavioral Intervention Effectiveness in Developing Countries  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a project in which we are conducting systematic reviews and meta-analysis on evidence of effectiveness of a variety of HIV behavioral interventions in developing countries.

Title: Phase II RCT of Comprehensive Triage HIV Prevention: Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The purpose of this study is to conduct a rigorous 3-year Phase II trial of a promising HIV prevention strategy designed to significantly reduce population-level HIV incidence in rural developing country settings with severe generalized HIV epidemics.

Title: Community-Based Combination HIV Prevention in Tanzania Women at Heightened Risk  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a two-arm Phase II community randomized controlled trial of a community-based combination HIV prevention intervention among FSWs in Iringa, Tanzania. The combination package examined includes integrated biomedical, behavioral and structural components: The study will establish base rates of key outcomes including HIV incidence and viral load suppression, examine the socio-structural and behavioral pathways of the intervention, assess feasibility, acceptability and safety, and document preliminary effectiveness. (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop- in-center to promote cohesion and collective action to reduce stigma and discrimination.

Title: Dyadic-Based Diagnosis, Care & Prevention for Discordant Couples in Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The primary goal for the proposed study is to examine the feasibility, safety, and impact on improved care and prevention of novel strategies to identify and engage HIV sero-discordant couples in an integrated prevention and treatment intervention.
Title: Bringing South African Men into HIV Counseling and Testing (HCT) and Care

Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800

Description: The ultimate objective of this research is to provide evidence-based strategies to improve treatment of HIV+ men. Treatment as prevention (TasP) can only work through a three step process: (1) Testing a significant proportion of the population, (2) linkage to care and (3) maintaining in care a significant proportion of HIV+ individuals to the point of viral suppression. The benefits of increased testing, linkage to and maintenance in care for men would be enormous. We propose a study that combines structural and individual level interventions and integrates the results to address our overall objective of maintenance in care to the point of viral suppression.

Aim 1: In a cluster-randomized study, we will investigate whether male-centered mobilization and testing increases the population-level percentage of men who have been tested (within the last 12 months) by more than 10 absolute percentage points. Aim 2: In the individually-randomized design, we will investigate whether POC CD4 testing and individualized case management improves linkage to care (immediately following diagnosis) and viral suppression (12 months later) over POC CD4 testing alone and standard of care. Aim 3: Integrate the results of the two trial components (Aims 1 and 2) to evaluate the joint effect of the interventions on the percentage of HIV+ men who are effectively tested, linked to care and maintained with undetectable VL. The benefits of increased testing, linkage to and maintenance in care for men would be enormous. Men would remain healthier longer, could work and support their families, contribute to rather than deplete household economic resources, raise their children, and they would be less likely to transmit HIV to female partners.

Title: A Pharmacokinetic Comparison of Immediate Release N-Acetylcysteine with Extended Release N-Acetylcysteine in Healthy Adults

Contact: Melissa Michel, michelm@musc.edu, 843-792-1901

Description: Healthy males and females between the ages of 18-50 years are asked to participate in a 12 day outpatient study. The purpose of the study is to determine if a newly developed extended release version of N-Acetylcysteine (NAC) will be acceptable to replace the currently available immediate release formulation of NAC.

Title: A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment

Contact: Melissa Michel, michelm@musc.edu, 843-792-1901

Description: This study is being done to collect information related to Major Depressive Disorder (MDD). The purpose of this observational study is to identify if answers to self-reported questionnaires about your symptoms and functioning, information about your daily activity and sleep quality, and speech and voice characteristics can be used to predict worsening of MDD in the near future.
ON GOING STUDIES

Title: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder.
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: This study is designed to evaluate the efficacy, safety, and tolerability of ALKS 3831 in schizophrenia with AUD. ALKS 3831 is a combination of olanzapine, an approved antipsychotic treatment for schizophrenia, and samidorphan, a new medication. Potential subjects for this trial are adults with a diagnosis of schizophrenia and alcohol use disorder (AUD) with a recent change in symptoms. The study will test whether olanzapine with samidorphan will aide in lowering alcohol use for subjects at the same time that the combination of the two drugs lessens side effects of olanzapine such as weight gain.

Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: The main purpose of this study is to assess the long-term safety, tolerability, and effectiveness of esketamine nasal spray plus a newly initiated oral (taken by mouth) antidepressant in patients with treatment-resistant depression. All patients in this study will be treated with esketamine nasal spray plus a new oral anti-depressant. The new oral anti-depressant will be one of the following approved and marketed oral antidepressants: duloxetine (Cymbalta), escitalopram (Lexapro), sertraline (Zoloft), or venlafaxine extended release (Effexor XR).
****Anticipated to start January 2016

Title: Internet Crimes Against Children: Development of a Typology of Offenders for Use in Prevention, Investigations and Treatment
Contact: Dr. Gregg Dwyer, 843-792-1461
Description: This study is based on the collection and analysis of data from Internet Crimes against Children (ICAC) investigated by ICAC Task Forces in 20+ states. The inferential analysis of perpetrator, victim and offense data and content analysis of Internet chats to solicit children serves to inform the mental health, social services, education and legal fields for use in forensic evaluations, treatment planning, criminal investigations, court proceedings and developing public safety strategies for protecting our communities’ youth. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2010-MC-CX-4003; joint with the University of So. Carolina.

Title: Protecting Children Online: Using Research-Based Algorithms to Prioritize Law Enforcement Internet Investigations
Contact: Dr. Dwyer. 843-792-1461
Description: Using data from ICAC Task Forces across the U.S. to develop empirically-based algorithms to assist law enforcement in prioritizing cases of: child pornography production over possession/distribution; online luring to meet a minor to commit sexual offenses, over luring restricted to online behavior such as sexual chat or exchanging pornographic images; hands-on sexual offense offenders against children over cases of offenders with no known history. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2011-MC-CX-0002; joint with University of South Carolina, Johns Hopkins University & University of Ottawa.
Title: Evaluation of Cue-Induced Brain Activation in Pedophilic Offenders  
Contact: Dr. Gregg Dwyer, 843-792-1461  
Description: This study adapts fMRI neuroimaging to evaluate cue-induced changes in regional brain activity in men with Pedophilic Disorder compared to men without the disorder. It has significant potential for knowledge acquisition. Neuroimaging technology has been used to a limited extent to address the neurobiological underpinnings of deviant sexual behavior, but studies are limited in number as well as in scope. It extends results of previous neuroimaging studies by assessing regional brain activity after cue stimulation with a control group during simultaneous fMRI and penile plethysmography. Funded by a University of Ottawa Medical Research Fund grant; joint with Royal’s Institute of Mental Health Research, University of Ottawa.

Title: Sexually Violent Predators” and the Impact of Substance Addiction: A Pilot Study  
Contact: Dr. Gregg Dwyer and Thomas Lewis III, 843-792-1461  
Description: This study evaluates persons committed under the South Carolina Sexually Violent predator (SVP) Act with regard to substance usage, mental health diagnoses, criminal justice, and sex offense data to better understand their relationships. By utilizing SVP Act Multidisciplinary Team review data, information can be obtained comparing persons recommended for commitment to those dismissed from the review process. Given the dearth of empirical study of this population, employing the depth and breadth of data to be examined will enable this pilot study to further the field and public safety efforts at the community level. The Principal Investigator for this study is a General Psychiatry Resident in the DART program with associated funding support.

Title: Enhancing the Identification of Victims of Child Pornography Production and Distribution  
Contacts: Drs. Gregg Dwyer, 843-792-1461  
Description: A unique collaboration with the National Center for Missing and Exploited Children has enabled access to data from a national registry of identified child pornography victims for the first time outside the federal government. The research team has built a database to examine characteristics of identified child pornography victims; how they are identified; relationships between child and perpetrator characteristics; details about the child pornography offenses. This is a multinational joint project with MUSC CPSPD, Royal’s Institute of Mental Health Research, University of Ottawa, Canada and School of Health in Social Science, University of Edinburgh, Scotland, UK. Funded by a Thorn Foundation grant.

Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder  
Contact: Donovan Katy donova@musc.edu (843) 724-2945  
Description: The goal of the study is to evaluate 3 fixed doses (5, 10 and 20 mg oral tablets) of vortioxetine (Brintellix) in the prevention of relapse in adult subjects (18-75 years old) with major depressive disorder (MDD), recurrent, who responded to acute treatment with vortioxetine. Eligible subjects participate in a 16-week open-label treatment period with vortioxetine followed by a 32-week double-blind randomized treatment phase.
ONGOING STUDIES

Title: Rivastigmine Patch in Veterans with Cognitive Impairment Following Traumatic Brain Injury
Contact: Donovan Katy donova@musc.edu (843) 724-2945
Description: In light of the significance of memory deficits in persons with Traumatic Brain Injury (TBI), and the strong relationship between posttraumatic memory impairments and posttraumatic cholinergic dysfunction, this study examines the efficacy and safety of cholinesterase inhibitor rivastigmine (transdermal patch), an intermediate-acting cholinesterase inhibitor, in Veterans (ages 19 – 65 years old) suffering from posttraumatic memory impairment following TBI in a multicenter, randomized placebo controlled 26-week trial.

Title: Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Contact: Olga Brawman-Mintzer, MD mintzero@musc.edu; (843) 724-2945
Description: Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is a Phase III, placebo-controlled, masked, 6 month, 10-center randomized clinical trial sponsored by National Institute of Aging involving 200 participants with Alzheimer's disease (AD). ADMET 2 is designed to examine the efficacy and safety of methylphenidate as treatment for clinically significant apathy in AD participants. ADMET 2 will enroll participants from real world settings such as outpatient, nursing home, and assisted living facilities and will examine the effects of methylphenidate on apathy and cognition. ADMET 2 will also conduct careful safety monitoring.
SUPPORTERS

Water’s Edge Dentistry
Excellence in Cosmetic, Restorative & Family Dentistry

"Dr D" is In-Network for the MUSC Health Plan
She proudly uses her award-winning talents to service the Lowcountry community.

Committed to giving you the smile you deserve:
- Family/General Dentistry
- Cosmetic Dentistry
- TMJ - Clenching/Grinding
- Sleep Apnea & Snoring
- Invisalign Braces
- Anxiety-Free Dentistry
- Botox/Dermal Fillers
- Teeth Whitening

Free In Office Whitening With New Patient Exam  Expires 3/1/16

WatersEdgeSC.com / 843.884.6166
1203 Two Island Court, #101, Mount Pleasant, SC 29466
(just off the Isle of Palms Connector)